Detect and monitor disease from clinically relevant change
at the sub-picogram level*

In drug discovery and development, the sooner you can quantitatively distinguish changes from normal, the faster you can make decisions.

Singulex offers a direct molecular detection technology that provides ultra-sensitive, robust immunoassays with an extensive clinical dynamic range. Required sample volume is small, and complex matrices such as serum can be assayed without depletion.  These advantages enable the rapid development of scalable, clinically translatable assays.

*Did we say sub-picogram level? Actually, some Singulex assays are even more sensitive, with new assays under development

NEWS

03/06/08 Singulex Collaborates With Large Pharmaceutical Company in Erenna™ Technology Access Program
Opens Facility to Support European Partnerships  more >

11/27/07 Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design  more >

11/16/07 Researchers at Washington U. Use System from Biotech Singulex Inc.  more >

11/14/07 Singulex Collaborates with Washington University School of Medicine to Advance Biomarker Research in Human Disease  more >

EVENTS & PRESENTATIONS

ADA 68th Scientific Sessions
2008-Jun-06 to 2008-Jun-10
San Francisco, CA

Join us at the 68th Scientific Session for the American Diabetes Association, held at the Moscone Convention Center in San Francisco, CA.   more >

BIO2008
2008-Jun-17 to 2008-Jun-20
San Diego, CA  more >

American Association of Pharmaceutical Scientists
2008-Jun-22 to 2008-Jun-25
Toronto, Ontario Canada  more >

AACC Annual Meeting 2008
2008-Jul-27 to 2008-Jul-31
Washington, DC

Join us as we present five posters with our ETAP collaborators at this year's AACC Annual Meeting in Washington, DC.  more >